Shares of CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report) passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $0.27 and traded as low as $0.24. CytoDyn shares last traded at $0.2415, with a volume of 1,142,436 shares.
CytoDyn Trading Down 1.3%
The business has a 50 day moving average of $0.27 and a two-hundred day moving average of $0.30. The firm has a market cap of $304.91 million, a P/E ratio of -24.15 and a beta of 1.33.
About CytoDyn
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Recommended Stories
- Five stocks we like better than CytoDyn
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Rare Earth Stocks: The Truce That Isn’t a Truce
- Energy and Oil Stocks Explained
- Carving Up Profits: 3 Food Stocks on the Thanksgiving Table
- What is the Shanghai Stock Exchange Composite Index?
- C3.ai’s Reset: Why New Leadership Could Spark a Turnaround
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
